PE20170893A1 - N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b - Google Patents

N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b

Info

Publication number
PE20170893A1
PE20170893A1 PE2017000506A PE2017000506A PE20170893A1 PE 20170893 A1 PE20170893 A1 PE 20170893A1 PE 2017000506 A PE2017000506 A PE 2017000506A PE 2017000506 A PE2017000506 A PE 2017000506A PE 20170893 A1 PE20170893 A1 PE 20170893A1
Authority
PE
Peru
Prior art keywords
alkylaryl
oxyaril
pirrol
negative allosteric
octahydro cyclopenta
Prior art date
Application number
PE2017000506A
Other languages
English (en)
Spanish (es)
Inventor
David R Anderson
Robert A Volkmann
Frank S Menniti
Original Assignee
Luc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55581945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Luc Therapeutics Inc filed Critical Luc Therapeutics Inc
Publication of PE20170893A1 publication Critical patent/PE20170893A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2017000506A 2014-09-26 2015-09-23 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b PE20170893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056284P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
PE20170893A1 true PE20170893A1 (es) 2017-07-12

Family

ID=55581945

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000506A PE20170893A1 (es) 2014-09-26 2015-09-23 N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b

Country Status (40)

Country Link
US (4) US10239835B2 (https=)
EP (4) EP3683207B1 (https=)
JP (5) JP6473227B2 (https=)
KR (1) KR102479356B1 (https=)
CN (1) CN106795111B (https=)
AP (1) AP2017009832A0 (https=)
AR (1) AR103199A1 (https=)
AU (1) AU2015320721B2 (https=)
BR (1) BR112017006093B1 (https=)
CA (1) CA2962569C (https=)
CL (1) CL2017000474A1 (https=)
CO (1) CO2017002494A2 (https=)
CR (1) CR20170114A (https=)
CU (1) CU24482B1 (https=)
CY (1) CY1123533T1 (https=)
DK (1) DK3197868T3 (https=)
EA (1) EA034937B1 (https=)
EC (1) ECSP17025302A (https=)
ES (3) ES2791327T3 (https=)
GT (1) GT201700062A (https=)
HR (1) HRP20200959T1 (https=)
HU (1) HUE049698T2 (https=)
IL (1) IL250909B (https=)
JO (1) JO3579B1 (https=)
LT (1) LT3197868T (https=)
MX (1) MX374657B (https=)
MY (1) MY182342A (https=)
NZ (1) NZ729569A (https=)
PE (1) PE20170893A1 (https=)
PH (1) PH12017500513A1 (https=)
PL (1) PL3197868T3 (https=)
PT (1) PT3197868T (https=)
RS (1) RS60497B1 (https=)
SG (1) SG11201702023QA (https=)
SI (1) SI3197868T1 (https=)
TN (1) TN2017000076A1 (https=)
TW (1) TWI687407B (https=)
UY (1) UY36326A (https=)
WO (1) WO2016049165A1 (https=)
ZA (1) ZA201701061B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
US12600726B2 (en) 2017-07-12 2026-04-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
AU2018360581A1 (en) 2017-10-31 2020-06-11 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN111788182B (zh) 2018-02-02 2023-09-26 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN111818928A (zh) 2018-03-05 2020-10-23 艾库斯生物科学有限公司 精氨酸酶抑制剂
TW202112378A (zh) * 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途
CN113906033B (zh) 2019-06-04 2024-04-02 勃林格殷格翰国际有限公司 咪唑并吡嗪衍生物及其作为药剂的用途
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途
CN116744922A (zh) * 2020-12-04 2023-09-12 诺华股份有限公司 Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
MX2023006567A (es) * 2020-12-04 2023-06-16 Novartis Ag Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion.
JP2021058765A (ja) * 2021-01-19 2021-04-15 株式会社藤商事 遊技機
CN117120053A (zh) * 2021-03-26 2023-11-24 诺华股份有限公司 新的环戊二烯并[c]吡咯NR2B负变构调节剂
EP4313041A4 (en) * 2021-03-26 2025-01-15 Novartis AG NEW CYCLOPENTAL[C PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B
AU2023278502A1 (en) 2022-06-02 2025-01-02 Novartis Ag Subcutaneous administration of onfasprodil and dosing methods for use in the treatment of depression disorders
IL322082A (en) 2023-01-12 2025-09-01 Novartis Ag Engineered ketoreductase polypeptides
TW202539663A (zh) 2023-12-06 2025-10-16 瑞士商諾華公司 用於治療抑鬱障礙之組成物和方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6369076B1 (en) * 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
RU2006146608A (ru) * 2004-06-09 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
AU2006236625A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl NMDA/NR2B antagonists
EP1849772A1 (en) 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
WO2007128458A1 (en) 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
KR101469306B1 (ko) * 2008-01-23 2014-12-04 장쑤 한서 파마슈티칼 캄파니 리미티드 다이사이클로아자알칸 유도체, 이의 제조 방법 및 의학적 용도
CA2746444A1 (en) 2008-12-12 2010-06-17 Vanderbilt University 3.3.0 bicyclic glyt1 inhibitors and methods of making and using same
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
BR112012016733A2 (pt) 2010-01-07 2015-09-01 Du Pont "composto, composição fungicida e método"
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
FR2974729B1 (fr) 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
US8501768B2 (en) 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
KR102032934B1 (ko) 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9418332B2 (en) 2013-08-16 2016-08-16 Qualcomm Incorporated Post ghost plasticity
WO2015048507A1 (en) * 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول

Also Published As

Publication number Publication date
ES2956546T3 (es) 2023-12-22
GT201700062A (es) 2019-09-30
ECSP17025302A (es) 2018-11-30
US20180111902A1 (en) 2018-04-26
BR112017006093B1 (pt) 2023-03-21
UY36326A (es) 2016-04-29
JP2017528502A (ja) 2017-09-28
EP3197868A1 (en) 2017-08-02
SI3197868T1 (sl) 2020-10-30
PH12017500513A1 (en) 2017-08-07
EP4282412A2 (en) 2023-11-29
RS60497B1 (sr) 2020-08-31
JP6772307B2 (ja) 2020-10-21
DK3197868T3 (da) 2020-06-22
ES2791327T3 (es) 2020-11-03
EP3683207B1 (en) 2021-12-29
JO3579B1 (ar) 2020-07-05
US20190152912A1 (en) 2019-05-23
CR20170114A (es) 2017-08-21
NZ729569A (en) 2019-06-28
EA034937B1 (ru) 2020-04-08
CA2962569C (en) 2023-09-19
LT3197868T (lt) 2020-09-10
JP2023052515A (ja) 2023-04-11
TN2017000076A1 (en) 2018-07-04
HRP20200959T1 (hr) 2020-10-02
WO2016049165A1 (en) 2016-03-31
CA2962569A1 (en) 2016-03-31
IL250909A0 (en) 2017-04-30
KR102479356B1 (ko) 2022-12-19
JP7216060B2 (ja) 2023-01-31
EP3197868B1 (en) 2020-04-15
CL2017000474A1 (es) 2017-08-18
AR103199A1 (es) 2017-04-26
US10781174B2 (en) 2020-09-22
CO2017002494A2 (es) 2017-08-31
AP2017009832A0 (en) 2017-03-31
MX374657B (es) 2025-03-06
SG11201702023QA (en) 2017-04-27
US20220274925A1 (en) 2022-09-01
MY182342A (en) 2021-01-20
EP3974420A1 (en) 2022-03-30
EP4282412A3 (en) 2024-01-17
US12145909B2 (en) 2024-11-19
EP3974420B1 (en) 2023-08-16
IL250909B (en) 2019-06-30
CN106795111A (zh) 2017-05-31
MX2017003940A (es) 2018-03-01
TW201625528A (zh) 2016-07-16
TWI687407B (zh) 2020-03-11
ES2911004T3 (es) 2022-05-17
CU20170037A7 (es) 2017-08-08
ZA201701061B (en) 2019-07-31
AU2015320721A1 (en) 2017-03-30
US10239835B2 (en) 2019-03-26
HUE049698T2 (hu) 2020-10-28
JP2019077713A (ja) 2019-05-23
CN106795111B (zh) 2020-04-07
AU2015320721B2 (en) 2020-01-30
CY1123533T1 (el) 2022-03-24
JP2025060835A (ja) 2025-04-10
PT3197868T (pt) 2020-05-21
EP3683207A1 (en) 2020-07-22
EP3197868A4 (en) 2018-04-25
CU24482B1 (es) 2020-03-04
JP6473227B2 (ja) 2019-02-20
JP2021006554A (ja) 2021-01-21
PL3197868T3 (pl) 2020-11-02
US20200369610A1 (en) 2020-11-26
BR112017006093A2 (pt) 2017-12-19
EA201790713A1 (ru) 2017-07-31
JP7612722B2 (ja) 2025-01-14
KR20170063599A (ko) 2017-06-08

Similar Documents

Publication Publication Date Title
PE20170893A1 (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostericos negativos de nr2b
CY1125539T1 (el) Παραγωγα αζετιδινης ως ρυθμιστες του υποδοχεα χημειοκινης και χρηση αυτων
PE20171329A1 (es) Agentes inmunorreguladores
PH12019502003A1 (en) Cyclic sulfamide compounds and methods of using same
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20181289A1 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20141974A1 (es) Compuestos de heterociclilo
PE20161206A1 (es) Derivado de urea o sal farmacologicamente aceptable del mismo
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
MX388533B (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
EA201170349A1 (ru) Модуляторы mif
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
PE20091103A1 (es) Inhibidores de la polimerasa virica
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
EA201491610A1 (ru) Модуляторы x рецепторов печени
EA202091120A2 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
EA201491609A1 (ru) Модуляторы x рецепторов печени
EA202191356A1 (ru) Усовершенствованные способы синтеза для получения конденсированных гетероциклических соединений в качестве модуляторов рецептора орексина